Project Grant SB1HL184525
Award Date 9/15/26
Completion Date 9/14/27
Dollars Obligated $496K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Fremont, CA 94538, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Fastline LLC $306,383 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and test a second-generation one-handed central venous line (CVL) placement device. Fastline is engineering a simplified CVL insertion device that enables operators to perform all steps of central vein access—needle puncture, aspiration/injection, manometry testing, and guidewire placement—with a single hand while...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Nimble Surgical Incorporated $314,362 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop FLEXLOCK, a manually operable anchoring guide catheter designed to simplify transradial complex percutaneous coronary interventions. FLEXLOCK delivers simultaneous active and passive support through an anchoring tip to provide stable coronary access during complex PCI...
- The National Heart, Lung, and Blood Institute awarded MDC Studio, Inc. $309,813 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an automated vascular access device that enables less-experienced providers to safely and reliably perform central venous and arterial cannulation. The R61 phase focuses on automating the core steps of successful cannulation. MDC Studio will design, construct, and test sensors and automation to detect blood vessel...
- The National Heart, Lung, and Blood Institute awarded Bridgesource Medical, Corp. $320,727 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a right heart catheter device that uses pressure-volume loop analysis to identify which patients with tricuspid regurgitation will benefit from percutaneous valve repair procedures. The device addresses a critical clinical gap in patient selection for tricuspid valve interventions. Approximately 1.5 million...
- The National Heart Lung and Blood Institute awarded Venostent, Inc. $1,016,974 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support pilot-scale synthesis and commercialization of SelfWrap, a bioabsorbable perivascular wrap designed to improve outcomes in arteriovenous fistula creation and other vascular surgeries. SelfWrap addresses the high failure rate of arteriovenous fistulas (AVFs) created for hemodialysis access. Veins used in AVF surgery are...
- The National Heart, Lung, and Blood Institute awarded Aust Development, LLC a Phase I Small Business Innovation Research project grant of $626,604 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). Aust Development will develop a novel 3D pre-shaped delivery catheter platform to enable precise identification and safe delivery of cardiac conduction system pacing leads. The delivery system will allow physicians to sequentially map the septal myocardium, fix...
- The National Heart, Lung, and Blood Institute awarded Ram Medical Innovations, Inc. $344,740 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop foundational engineering and preclinical data for a coronary sheath stabilization device. The Coronary M-Y Sheath is designed to address limitations in complex percutaneous coronary interventions by providing active stabilization through a proprietary anchoring mechanism that leverages two vascular access...
- Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $737,415 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the association between hospital market competition and inappropriate vascular surgical care in older adults. The recipient will conduct a research study analyzing overtreatment patterns in two conditions: abdominal aortic aneurysm (AAA) repair at small sizes not supported...
- The National Heart, Lung, and Blood Institute awarded Nytricx, Inc. $314,337 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer nitric oxide-releasing intravascular catheters with solid slippery surfaces designed to combat infection and thrombosis in short-term applications. Nytricx, Inc., a self-certified small disadvantaged business headquartered in Athens, Georgia, specializes in nitric oxide release polymer technologies for advanced medical...